Baird served as co-manager on this offering
AboutTESARO, Inc. (“TESARO” or the “Company”) (NASDAQ: TSRO) recently completed a follow-on offering of 5,428,000 shares of common stock at a price of $18.00 per share, generating gross proceeds of approximately $97.7 million. The Company intends to use the net proceeds from the offering to fund its development programs, including clinical trials for its product candidates, rolapitant, niraparib and TSR-011; and for working capital and general corporate purposes.
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. TESARO has in-licensed and is currently developing three product candidates; rolapitant, niraparib and TSR-011. The Company’s lead product candidate, rolapitant, is currently in Phase 3 clinical trials for the prevention of chemotherapy induced nausea and vomiting. The Company intends to continue to leverage the experience and competencies of its senior management team to identify, acquire, develop and commercialize cancer therapeutics and oncology supportive care products that are safer and more effective than existing treatments. TESARO is based in Waltham, Massachusetts.
For additional information about this transaction, please contact:
- March 2013
- TESARO, Inc.
- Target Location
- North America